Study shows heart failure treatment with dapagliflozin consistently benefited both men and women

9 November 2022

Clinical outcomes for 11,007 randomized patients, 35 of whom were women, were compared by sex across the spectrum of left ventricular ejection fraction. In both DAPA-HF and DELIVER, men and women responded similarly and positively to dapagliflozin when it came to primary outcomes of worsening HF or cardiovascular death, and secondary outcomes of general health status.

"Given the consistency of our trial with other SGLT2 inhibitor trials like EMPEROR, sex-specific indications may not be needed for this class of HF therapies in the future," said lead author Xiaowen (Wendy) Wang, MD, of the Division of Cardiovascular Medicine. "We are pleased dapagliflozin was safe and well-tolerated in both sexes, with improvement in clinical outcomes and health status."

The study is published in Circulation.


Provided by Brigham and Women's Hospital

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.